18 · Industry

Pharmaceuticals & Biotechnology

Pharmaceuticals & Biotechnology brings legal and Financial Crime exposure into the same operating environment as research, clinical development, market access, healthcare professionals, distributors, data, pricing and product integrity. For your organisation, the key question is whether Life Sciences Governance, Three Lines Integration & Executive Accountability, Anti-Bribery, HCP/HCO Interactions, Grants & Sponsorships, and Clinical Trials, Research Integrity, Site Payments & Data Reliability are connected early enough to identify material exposure before it becomes a regulatory, criminal, operational or reputational event.

FACTCONTEXTRISKNORMCONTROLDECISIONEVIDENCEASSURANCEREMEDIATIONLEARNING
Legal-strategic perspective

Pharmaceuticals & Biotechnology brings legal and Financial Crime exposure into the same operating environment as research, clinical development, market access, healthcare professionals, distributors, data, pricing and product integrity. For your organisation, the key question is whether Life Sciences Governance, Three Lines Integration & Executive Accountability, Anti-Bribery, HCP/HCO Interactions, Grants & Sponsorships, and Clinical Trials, Research Integrity, Site Payments & Data Reliability are connected early enough to identify material exposure before it becomes a regulatory, criminal, operational or reputational event. The control architecture must also account for Market Access, Pricing, Reimbursement & Commercial Integrity, Distributors, Agents, Third Parties & Cross-Border Corruption Risk, and Sanctions, Export Controls, Supply Chains & Geopolitical Exposure, while Manufacturing Integrity, Counterfeit Risk & Product Diversion, M&A, Licensing, Partnerships & Post-Acquisition Compliance Risk, Internal Investigations, Regulatory Enforcement & Litigation, and Continuous Assurance, Remediation & Life-Sciences Transformation determine whether decisions remain supported by reliable data, evidence, escalation and assurance. Van Leeuwen Law Firm approaches Pharmaceuticals & Biotechnology through an integrated legal, forensic and governance lens so that sector-specific risk is translated into clear ownership, proportionate controls and defensible executive decisions.

The ten substantive anchors on this page are treated as connected parts of one governance and risk problem. For this industry, the objective is to connect legal analysis, facts, data, ownership, decision rights, controls and evidence so that material exposure can be recognised early, challenged independently and translated into action that remains defensible under later scrutiny.

10

10 key subthemes

These ten themes are the substantive anchors for legal analysis, governance, decision-making, execution and assurance.

  1. 01Life Sciences Governance, Three Lines Integration & Executive Accountability
  2. 02Anti-Bribery, HCP/HCO Interactions, Grants & Sponsorships
  3. 03Clinical Trials, Research Integrity, Site Payments & Data Reliability
  4. 04Market Access, Pricing, Reimbursement & Commercial Integrity
  5. 05Distributors, Agents, Third Parties & Cross-Border Corruption Risk
  6. 06Sanctions, Export Controls, Supply Chains & Geopolitical Exposure
  7. 07Manufacturing Integrity, Counterfeit Risk & Product Diversion
  8. 08M&A, Licensing, Partnerships & Post-Acquisition Compliance Risk
  9. 09Internal Investigations, Regulatory Enforcement & Litigation
  10. 10Continuous Assurance, Remediation & Life-Sciences Transformation
Strategic depth

From substantive anchors to governable choices

The four blocks below connect the ten page-specific subthemes with materiality, decision-making, governance, execution and the evidential position your organisation may later need to defend.

01

Integrated Financial Crime Risk Management

Life Sciences Governance, Three Lines Integration & Executive AccountabilityAnti-Bribery, HCP/HCO Interactions, Grants & SponsorshipsClinical Trials, Research Integrity, Site Payments & Data Reliability

Within Pharmaceuticals & Biotechnology, Integrated Financial Crime Risk Management is not a separate compliance layer. It is the discipline of connecting legal, operational and integrity exposure through one coherent factual and risk picture. The substantive anchors in this block are Life Sciences Governance, Three Lines Integration & Executive Accountability, Anti-Bribery, HCP/HCO Interactions, Grants & Sponsorships, and Clinical Trials, Research Integrity, Site Payments & Data Reliability. For Life Sciences Governance, Three Lines Integration & Executive Accountability, ownership, independent challenge, decision rights, escalation and management information must be designed so that responsibility remains clear and material decisions can later be reconstructed from reliable evidence. For Anti-Bribery, HCP/HCO Interactions, Grants & Sponsorships, behavioural, identity, payment and network indicators must be combined early enough to protect assets and victims, while investigation, blocking, reporting and recovery decisions remain legally controlled and evidentially traceable. For Clinical Trials, Research Integrity, Site Payments & Data Reliability, data quality, lineage, access control, model and cyber risk, explainability, logging and digital evidence integrity determine both operational effectiveness and the defensibility of later decisions.

For this industry, this means signals from the business, Legal, Compliance, Finance, Data, Technology and investigations should not remain separated when they relate to the same customer, transaction, third party, event or decision. Control quality is therefore assessed by whether material exposure is recognised in time, ownership is clear and decisions are supported by sufficient facts and evidence—not by the number of isolated controls in place.

02

Governance, Three Lines and decision-making

Market Access, Pricing, Reimbursement & Commercial IntegrityDistributors, Agents, Third Parties & Cross-Border Corruption RiskSanctions, Export Controls, Supply Chains & Geopolitical Exposure

Governance within Pharmaceuticals & Biotechnology becomes effective only when formal responsibility is visible in actual decision-making. The anchors Market Access, Pricing, Reimbursement & Commercial Integrity, Distributors, Agents, Third Parties & Cross-Border Corruption Risk, and Sanctions, Export Controls, Supply Chains & Geopolitical Exposure determine how First Line ownership, independent Second Line challenge and Third Line assurance can operate from a common factual base without losing role clarity. For Market Access, Pricing, Reimbursement & Commercial Integrity, the issue must be translated into verifiable facts, explicit ownership, materiality criteria, proportionate controls, clear escalation and evidence capable of supporting later review. For Distributors, Agents, Third Parties & Cross-Border Corruption Risk, behavioural, identity, payment and network indicators must be combined early enough to protect assets and victims, while investigation, blocking, reporting and recovery decisions remain legally controlled and evidentially traceable. For Sanctions, Export Controls, Supply Chains & Geopolitical Exposure, sanctions regimes, ownership and control, indirect exposure, circumvention indicators, geographic context, end-use and escalation thresholds must be brought together in one auditable factual picture.

Van Leeuwen Law Firm translates this into decision rights, escalation criteria, management information, exception governance and a traceable record of executive judgement. The result is not a paper Three Lines model, but a governance cycle in which information moves between the lines, challenge is demonstrable and residual risk is explicitly accepted, reduced or terminated.

03

Strategic direction and enterprise-wide embedding

Manufacturing Integrity, Counterfeit Risk & Product DiversionM&A, Licensing, Partnerships & Post-Acquisition Compliance Risk

The strategic value of Pharmaceuticals & Biotechnology arises when Manufacturing Integrity, Counterfeit Risk & Product Diversion and M&A, Licensing, Partnerships & Post-Acquisition Compliance Risk are directly connected to enterprise choices, investment priorities, capacity and the operating model. For Manufacturing Integrity, Counterfeit Risk & Product Diversion, the issue must be translated into verifiable facts, explicit ownership, materiality criteria, proportionate controls, clear escalation and evidence capable of supporting later review. For M&A, Licensing, Partnerships & Post-Acquisition Compliance Risk, strategic ambition, legal feasibility, materiality, risk appetite, alternatives and escalation criteria should be translated into explicit decision rules before exposure becomes embedded.

That requires an explicit relationship between risk appetite, legal constraints, commercial or institutional objectives and the resources needed for controls to operate in practice. Van Leeuwen Law Firm therefore focuses on which option is legally executable and institutionally defensible, which residual risk remains and which evidence is needed to sustain the chosen course under regulatory review, investigation or dispute.

04

Integrity steering in a structurally changing risk landscape

Internal Investigations, Regulatory Enforcement & LitigationContinuous Assurance, Remediation & Life-Sciences Transformation

The control environment around Pharmaceuticals & Biotechnology must remain adaptive because Internal Investigations, Regulatory Enforcement & Litigation and Continuous Assurance, Remediation & Life-Sciences Transformation are continuously affected by technological change, cyber threats, geopolitics, sanctions, evolving data, regulatory change and third-party dependencies. For Internal Investigations, Regulatory Enforcement & Litigation, scope, independence, privilege, preservation, chain of custody, interviews, documentation and evidential assessment are central to moving from allegation to a reliable factual record and a defensible enforcement or litigation position. For Continuous Assurance, Remediation & Life-Sciences Transformation, the focus moves from identifying deficiencies to root-cause analysis, demonstrable remediation, independent validation, sustainable embedding and management information on residual risk and effectiveness.

Effective integrity steering therefore requires continuous sensing, periodic recalibration of scenarios, integration of incidents and investigation findings into risk models, and timely adjustment of governance and controls. Change is then not processed only after an incident; it is systematically translated into revised assumptions, decision thresholds, controls, training, assurance and board-level information.

Your next step

Discuss your matter

Van Leeuwen Law Firm connects legal analysis, facts, evidence, governance and strategic execution around your specific matter.

Facts and evidenceExecutive decision spaceExecutable next steps
Contact Van Leeuwen Law Firm →

← Back to overview